RT Journal Article
T1 Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.
A1 Gomez-Bravo, Miguel
A1 Prieto Castillo, Martin
A1 Navasa, Miquel
A1 Sanchez-Antolin, Gloria
A1 Llado, Laura
A1 Otero, Alejandra
A1 Serrano, Trinidad
A1 Jimenez Romero, Carlos
A1 Garcia Gonzalez, Miguel
A1 Valdivieso, Andres
A1 Gonzalez-Dieguez, Maria Luisa
A1 de la Mata, Manuel
A1 Pons, Jose A
A1 Salcedo, Magdalena
A1 Rodrigo, Juan M
A1 Cuervas-Mons, Valentin
A1 Gonzalez Rodriguez, Antonio
A1 Caralt, Mireia
A1 Pardo, Fernando
A1 Varo Perez, Evaristo
A1 Crespo, Gonzalo
A1 Rubin, Angel
A1 Guilera, Magda
A1 Aldea, Anna
A1 Santoyo, Julio
K1 Everolimus
K1 De novo liver transplant
K1 Renal function
K1 eGFR
K1 KDIGO
AB Reduction in calcineurin inhibitor levels is considered crucial to decrease the incidence of kidney dysfunction in liver transplant (LT) recipients. The aim of this study was to evaluate the safety and impact of everolimus plus reduced tacrolimus (EVR + rTAC) vs. mycophenolate mofetil plus tacrolimus (MMF + TAC) on kidney function in LT recipients from Spain. the REDUCE study was a 52-week, multicenter, randomized, controlled, open-label, phase 3b study in de novo LT recipients. Eligible patients were randomized (1:1) 28 days post-transplantation to receive EVR + rTAC (TAC levels ≤ 5 ng/mL) or to continue with MMF + TAC (TAC levels = 6-10 ng/mL). Mean estimated glomerular filtration rate (eGFR), clinical benefit in renal function, and safety were evaluated. in the EVR + rTAC group (n = 105), eGFR increased from randomization to week 52 (82.2 [28.5] mL/min/1.73 m2 to 86.1 [27.9] mL/min/1.73 m2) whereas it decreased in the MMF + TAC (n = 106) group (88.4 [34.3] mL/min/1.73 m2 to 83.2 [25.2] mL/min/1.73 m2), with significant (p  EVR + rTAC allows a safe reduction in tacrolimus exposure in de novo liver transplant recipients, with a significant improvement in eGFR but without significant differences in renal clinical benefit 1 year after liver transplantation.
PB Sociedad Española de Patologia Digestiva
SN 1130-0108
YR 2022
FD 2022-04-05
LK http://hdl.handle.net/10668/21725
UL http://hdl.handle.net/10668/21725
LA en
NO Gómez-Bravo M, Prieto Castillo M, Navasa M, Sánchez-Antolín G, Lladó L, Otero A, et al. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. Rev Esp Enferm Dig. 2022 Jun;114(6):335-342
DS RISalud
RD Apr 10, 2025